Teena Chopra, MD, MPH, Co-Director Medical Education Junior Infection Fighters Program
Maureen Spencer, M. Ed, BSN, RN, CIC, FAPIC, Co-Director Medical Education Junior Infection Fighters Program
Dayle Skelly, BA, C. diff. Survivor, Director Junior Infection Fighters Program
A stellar example of teamwork in coordinating the study, developing educational material, and introducing the children to educational activities focused on healthy-habits and preventing infections.
“None of us can do this alone ~ All of us can do this together.”
We express our gratitude and applaud all who have continued to demonstrate their professional skills, leadership, tireless efforts, and unfailing dedication in areas of specialization and even more so during these unprecedented times.
We are more than grateful to those who forge ahead for the sake of others in need seeking medical care and resolution of this life-threatening infection.
Wishing you good health and continued success.
Nancy Nancy C Caralla Founding President, Executive Director
C Diff Foundation is pleased to announce the Michael and Helen Caralla, Sr. Educational Scholarship program. The scholarship program is to help health care students succeed and reach their educational goals.
To apply for a C Diff Foundation
Michael and Helen Caralla, Sr. Educational Scholarship,
the applicant must submit an application
by May 1 of each calendar year.
The C Diff Foundation selection committee chooses application recipients based on a submitted essay, letters of recommendation, a willingness to complete the Volunteer Service project to promote C. difficile infection awareness requirement, and financial need.
Awards consist of annual scholarships that range in value from $750 to $1,500 USD. Recipients must reapply each year they attend post-secondary school and will be chosen based on their academic progress and mentoring performance.
To be eligible for a Michael and Helen Caralla, Sr. Educational Scholarship the applicant must be:
A student and a high school graduate or have a General Educational Development a.k.a. General Educational Diploma (GED).
Enrolled full-time at an accredited post-secondary educational institution during the 2017-2018 academic year (If a foreign student is applying and is chosen, the educational scholarship awarded amount will be converted from USD to the educational institute location foreign currency exchange rate and proof of country residency must be provided).
Maintain full-time status throughout the 2017-2018 academic year in order to remain eligible.
Willing to complete a minimum of 50 volunteer hours promoting C. difficile infection prevention, treatments, and environmental safety awareness in their local communities per academic year awarded the educational scholarship.
C. difficile infections can be acquired and diagnosed in infants and across the life-span with a higher risk involving our senior citizens and that is why it is imperative to learn about a C. difficile infection, its most common symptoms, the treatments available, and environmental safety products to prevent the spread of this spore-bacteria and to help reduce C. difficile infection recurrences.
“When you apply to become a C Diff Foundation Scholar, you are taking the first step to determine your own future. The C Diff Foundation Scholars are individuals motivated and dedicated to making a difference in the health care community. We are excited to offer a scholarship program to help support health care students to advance their career path through the Michael and Helen Caralla, Sr. educational scholarship, a program in memory of our loving parents,” states Nancy C Caralla, Executive Director.
About the C Diff Foundation:
The C Diff Foundation, a 501(c)(3) non-profit, founded in 2012 by Nancy C Caralla, a nurse diagnosed and treated for Clostridium difficile (C. diff.) infections.
Through her own CDI journeys and witnessing the passing of her father, diagnosed with sepsis secondary to C. difficile infection involvement, Nancy recognized the need for greater awareness through education, the research being conducted by the government, industry, and academia and better advocacy on behalf of patients, healthcare professionals, and researchers worldwide working to address the public health threat posed by this devastating infection.
For additional Scholar Applicant information, visit the C Diff Foundation website
The C Diff Foundation Volunteer Patient Advocates; Heather Clark and
her sister, Kimberly Reilly participated at local events over the summer season to educate and advocate
for C. diff. infection prevention, treatments, and environmental safety within the local communities raising C. diff. awareness and saving lives.
On behalf of the C Diff Foundation , we sincerely thank you Heather and Kimberly for your dedication, your time, and for joining the
C Diff Foundation partnering and sharing our global mission.
We are truly grateful to the many special Volunteer Patient Advocates, the special individuals donating their time in “Raising C. diff. Awareness within their communities” around the globe. Thank You!
Heather and Kimberly lost their dear Father from C.diff. involvement. Shortly after his passing, Heather and Kimberly took a stand with the C Diff Foundation and dedicated their time and efforts in “Raising C. diff. Awareness” to help educate, and advocate for this life-threatening infection that played a big part in their Father’s passing.
To listen to Heather’s journey, with fellow C. diff. survivors, – please click on the podcast link below:
Clostridium difficile (C.diff.) is gram-positive, anaerobic, and a spore, rod/spindle-shape,
a common bacterium of the human intestine in 2 – 5%. C diff. becomes a serious gastrointestinal infection when individuals have been exposed to antibiotic therapy, and/or have experienced a long-term hospitalization, and/or have had an extended stay in a long-term care facility. However; the risk of acquiring a C diff. infection (CDI) has increased as it is in the community (Community Acquired CDI) and found in outpatient settings.
There are significant risk factors in patients who are immunosuppressant, ones who have been on antibiotic therapy, and the elderly population.
How do Antibiotics cause C diff.? The antibiotics cause a disruption in the normal intestinal flora which leads to an over growth of C difficile bacteria in the colon. The leading antibiotics known to disrupt the normal intestinal flora, yet not limited to, are Ampicillin, Amoxicillin, Cephalosporins, Clindamycin, and the broad spectrum antibiotics.
Since November 2012 the CDC has shared public announcements regarding antibiotic use: Colds and many ear and sinus infections are caused by viruses, not bacteria. Taking antibiotics to treat a “virus” can make those drugs less effective when you and your family really need them. Limiting the usage of antibiotics will also help limit new cases of CDI.
*Always discuss the symptoms and medications with the treating Physician.
What are C.diff. Symptoms? Symptoms of Clostridium difficile (C.diff.) C.diff. strains produce several toxins; the most popular are enterotoxin – Clostridium difficile toxin A and cytotoxin – Clostridium difficile toxin B. Both strains are responsible for the symptoms of diarrhea, abdominal pain, fever, fatigue, and can advance to a complication of a severe inflammation of the colon; pseudomembranous colitis, which can also lead to further complications of toxic megacolon.
How is C.diff. Transmitted? Mode of transmission of CDI can be either directly or indirectly, hospital acquired (nosocomial) or community – acquired; Ingesting C.diff spores transmitted from others and patients by hands, or altered normal intestinal flora by antibiotic therapy allowing proliferation of C.diff. in the colon. Coming in contact with surfaces, devices, or material with Clostridium difficile spores can easily be transferred to individuals by hands that have touched a contaminated surface or item. Examples of surfaces, devices, and materials contaminated with C.diff. spores in hospital and community/outpatient settings: commodes, bath tubs, showers, hand rails, bed rails, counter tops, handles, clothing, medical equipment, and electronic rectal thermometers.
The C Diff Foundation provide a wide range of programs, such as education, and advocacy for C. diff. infection prevention, treatments, support, and environmental safety worldwide, training of volunteer patient advocates (VPA’s) across the globe to provide educational workshops, supplying life-saving medications for those afflicted with this infection from young children to seniors, building satellite branches across the globe, presenting educational workshops in educational programs, improving and expanding the C. difficile infection awareness, providing global tele-conferencing support sessions in mental health counseling, long-term illnesses, the prevention, treatments, environmental safety with nutritional education for patients, and families suffering through a C. difficile infection
and so much more.
We are working together and dedicated at raising C. diff. awareness to witness a decrease in newly diagnosed C. difficile infections worldwide and through dedication and efforts of the
C Diff Foundation Volunteers – we will meet our goals.
Treatments For CDI? Treating C diff is becoming more challenging to physicians, frustrating to patients, and costly to the health care industry. To date there are three antibiotics effective at treating C diff: Metronidazole is prescribed to treat mild to moderate symptoms and is cost effective (8). Vancomycin is prescribed for moderate to severe symptoms via: oral route as intravenous administration does not achieve gut lumen therapeutic levels. Vancomycin is prescribed to patients with unsuccessful results from the Metronidazole, or the patient is allergic, or pregnant, breastfeeding, or younger than ten years of age.
The most recent antibiotic, Dificid (fidaxomicin) http://www.dificid.com is the first medication approved by FDA to treat C diff. Associated-Diarrhea CDAD in over twenty five years with superiority in sustained clinical response (5) Loperamide, diphenoxylate and bismuth medications are contraindicated as they slow the fecal transit time which extends the toxins in the gastrointestinal system.
The use of Cholestyramine has demonstrated positive results as toxins A and B bind to the resin as it passes through the intestines aiding in slowing bowel motility and assists in decreasing dehydration (9).
C.diff. spores are able to live outside of the body for a very long period of time and are resistant to most routine cleaning agents. It has also been proven that alcohol based hand sanitizers remain ineffective in eradicating C. diff. spores. In 2009 Clorox Commercial Solutions Ultra Clorox Germicidal Bleach ® was named the first and only product to obtain Federal EPA registration for killing C. diff. spores on hard, non porous surfaces when used as directed (1).
Please visit the following Page for additional information:
The CDC also recommends a 1:10 ( 1 cup bleach to 9 cups of water) dilution of bleach and water for cleaning hard non-porous surfaces keeping areas covered with solution for 10 minutes and the solution is to be mixed fresh daily.
Hand hygiene following the guidelines in HAND WASING; it is important to wash hands before entering and exiting a patient’s room (4). The spores are difficult to remove from hands; Universal Contact Precautions remain best practice for healthcare personnel and Contact Precautions for patients with a confirmed diagnosis of CDI. Prevention through education about CDI has proven effective and beneficial to environmental housekeeping departments, health care professionals, administration, patients, and their families (2)
CLICK ON THE LOGO TO BE REDIRECTED TO LISTEN TO THE BROADCAST
Listen in to the live broadcast at 10a PT, 11a MT, 12p CT, 1p ET 6p UK
“C. diff. Spores and More,” Global Broadcasting Network – innovative and educational interactive healthcare talk radio program discusses
The Role of the Microbiome in Health and Disease: The Basics
With Our Guest
Dr. Matthew Henn, Senior Vice President, Head of Drug Discovery and Bioinformatics
Matthew Henn is the Senior Vice President and Head of Drug Discovery & Bioinformatics of Seres Therapeutics, Inc. He has more than 16 years of combined research experience in microbial ecology, genomics, and bioinformatics that spans both environmental and infectious disease applications.
Dr. Henn’s research has focused on the development, implementation, and application of genomic technologies in the area of microbial populations and their metabolic functions. Prior to joining Seres, he was the Director of Viral Genomics and Assistant Director of the Genome Sequencing Center for Infectious Diseases at the Broad Institute of MIT and Harvard.
Join us on Tuesday, July 19th as Dr. Henn provides the foundation educational information about the microbiome by answering the fundamental questions of what is it, why is it important, how does it impact patients with C. difficile infections, and what are the possibilities of the microbiome as a therapeutic target for future drugs. This interview will solely be with Dr. Matthew Henn, Senior Vice President and Head of Drug Discovery & Bioinformatics at Seres Therapeutics, Inc,.
Seres Therapeutics is a leading microbiome therapeutics company dedicated to creating a new class of medicines to treat diseases resulting from imbalances in the microbiome. These first-in-class drugs, called Ecobiotics®, are ecological compositions of beneficial organisms that are designed to restore a healthy human microbiome. The discovery efforts at Seres Therapeutics currently span metabolic, inflammatory, and infectious diseases.
“C. diff. Spores and More “ Global Broadcasting Network spotlights world renowned topic experts, research scientists, healthcare professionals, organization representatives,C. diff. survivors, board members, and C Diff Foundation volunteers who are all creating positive changes in the C. diff. community worldwide.
Through their interviews, the C Diff Foundation mission will connect, educate, and empower many worldwide.
Questions received through the show page portal will be reviewed and addressed by the show’s Medical Correspondent, Dr. Fred Zar, MD, FACP, Dr. Fred Zar is a Professor of Clinical Medicine, Vice Head for Education in the Department of Medicine, and Program Director of the Internal Medicine Residency at the University of Illinois at Chicago. Over the last two decades he has been a pioneer in the study of the treatment of Clostridium difficile disease and the need to stratify patients by disease severity.
Access this program Podcast on C. diff. Spores and More Global Broadcasting Network by clicking on the logo above *
“Sepsis – Number One Preventable Cause of Death Worldwide”
On Tuesday, April 5th our guests Dr. Niranjan “Tex” Kissoon and Sepsis Survivor Ray Schachter discussed Sepsis – Number One Preventable Cause of Death Worldwide.
In this episode Tex Kissoon, MD,a well-known physician from Canada, provided us with the insight into the global phenomenon of Sepsis. Sepsis affects more than 30 million lives per year yet it is almost unknown to the general public and is quite often misdiagnosed by medical professionals worldwide. The reasons of why that is with the “why” Sepsis is so deadly, and what you can do to increase Sepsis awareness– were discussed in 60 minutes. Dr. Kissoon was joined by Ray Schachter, a Sepsis survivor who now dedicates all of his available time raising awareness of Sepsis worldwide. Both guests are members of the Global Sepsis Alliance (GSA), which has established World Sepsis Day on September 13thevery year to raise awareness for Sepsis worldwide.
About Our Guests:
Dr. Niranjan “Tex” Kissoon, MD
Dr. Kissoon is the Past President of the World Federation of Pediatric Critical and Intensive Care Societies, Vice-President, Medical Affairs at BC Children’s Hospital and Professor, Pediatric and Surgery (Emergency Medicine) Department of Pediatrics at the University of British Columbia in Vancouver, BC as well as he holds the University of British Columbia BC Children’s Hospital (UBC BCCH) Endowed Chair in Acute and Critical Care for Global Child Health. Dr. Kissoon is the vice chair of the Global Sepsis Alliance, co-chair of World Sepsis Day and the International Pediatric Sepsis Initiative.). He has been involved in both advocacy and in promoting Canada-wide involvement in World Sepsis Day as part of a global initiative. He is also involved in promoting sepsis guidelines such that appropriate treatments are given even in areas where there are limited resources.
Dr. Kissoon was awarded a Distinguished Career Award by the American Academy of Pediatrics in 2013 for his contribution to the society and discipline as well as the prestigious Society of Critical Care Medicine’s (SCCM) Master of Critical Care Medicine award in 2015 in recognition of his tireless efforts and achievements as a prominent and distinguished leader of national and international stature. He was also awarded the BNS Walia PGIMER Golden Jubilee Oration 2015 Award for major contribution to Pediatrics in India from the Postgraduate Institute Medical Education and Research.
A Direct Quote From Our Guest and Sepsis Survivor; Ray Schachter:
“I miraculously survived acute Sepsis in 1996 due to extensive medical intervention and have experienced the immediate and long-term consequences on me and my family. I am the Chair of the Global Sepsis Alliance (GSA) Task Force whose goal is to have the UN mandate Sepsis as a World Health Day. Working with these very accomplished and committed people from GSA, many of whom are on the GSA Executive or Ambassadors, on this important project is a very special opportunity.”
About The Global Sepsis Alliance (GSA):
Sepsis is one of the most underestimated health risks. It affects more than 30 million people worldwide each year; for 6 to 8 million of them with a fatal outcome. Surviving patients often suffer for years from late complications.
This is all the more disturbing as sepsis incidence could be considerably reduced by some simple preventive measures such as vaccination and improved adherence to hygiene standards, early recognition and optimized treatment. The main danger of sepsis results from a lack of knowledge about it.
The founding members of the Global Sepsis Alliance (GSA) have recognized the need to elevate public, philanthropic and governmental awareness and understanding of sepsis and to accelerate collaboration among researchers, clinicians, associated working groups and those dedicated to supporting them. For this reason, they initiated the Global Sepsis Alliance in 2010. Together with supporting organizations from across the globe, we are united in one common goal:
The GSA wants to ensure that:
The incidence of sepsis decreases globally by implementation of strategies to prevent sepsis.
Sepsis survival increases for children (including neonates) and adults in all countries through the promotion and adoption of early recognition systems and standardized emergency treatment
Public and professional understanding and awareness of sepsis improve
Access to appropriate rehabilitation services improve for all patients worldwide
The measurement of the global burden of sepsis and the impact of sepsis control and management interventions improve significantly
The GSA Current priorities:
Acknowledgement of a resolution on sepsis including official designation of World Sepsis Day (WSD) as one of the World Health Days by the World Health Assembly.
Recognition of sepsis in the Global Burden of Disease Report
Increase of public awareness and implementation of quality improvement initiatives
Our special thanks to GSAGeneral Manager: Marvin Zick for his assistance in coordinating this important episode with the C. diff. Spores and More team.
“C. diff. Spores and More,” Global Broadcasting Network – innovative and educational interactive healthcare talk radio program.
The “C. diff. Spores and More” program is made possible
by official Sponsor: Clorox Healthcare
Click on the above logo to learn more about Clorox Healthcare Products